GLP-1s may not only help people by reducing alcohol intake, but also protect the liver from alcohol metabolism-mediated damage, says one coauthor of that study, Wajahat Mehal, MD, who directs the Yale Fatty Liver Disease Program and the Yale Metabolic Health and Weight Loss Program in New Haven, Connecticut
Patients should maintain open communication with their healthcare team throughout semaglutide treatment
When to seek medical advice: If you experience muscle pain, weakness, or dark urine whilst taking statins (potential signs of myopathy) If severe, persistent abdominal pain occurs whilst on GLP-1 therapy (potential pancreatitis) If cholesterol reduction is not achieved despite treatment adherence Before stopping or changing any prescribed medication If you develop new symptoms or side effects from any therapy Patients should discuss their individual cardiovascular risk profile and treatment options with their GP or specialist
Retatrutide builds on earlier incretin research that first focused on GLP-1 receptor activity, then expanded to dual GLP-1/GIP agonists